首页> 外文期刊>Journal of Clinical Oncology >Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells.
【24h】

Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells.

机译:强度降低后再造血细胞同种异体移植后,复发性外周T细胞非霍奇金淋巴瘤的移植物抗淋巴瘤效果。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of malignancies characterized by a poor prognosis. We performed a pilot study to investigate the role of reduced-intensity conditioning (RIC) followed by allogeneic stem-cell transplantation in relapsed or refractory PTCLs. PATIENTS AND METHODS We have conducted a phase II trial on 17 patients receiving salvage chemotherapy followed by RIC and allogeneic transplantation of hematopoietic cells. The RIC regimen consisted of thiotepa, fludarabine, and cyclophosphamide. The acute graft-versus-host disease prophylaxis consisted of cyslosporine and short course methotrexate. Results Patients had a median age of 41 years (range, 23 to 60 years). Two patients were primary chemorefractory, and 15 had relapsed disease; eight patients (47%) had a disease relapse after an autologous transplantation. After a median follow-up of 28 months from the day of study entry (range, 3 to 57 months), 14 of 17 patients were alive (12 in complete remission, one in partial remission, and one with stable disease), two died as a result of progressive disease, and one died as a result of sepsis concomitant to acute graft-versus-host disease. The estimated 3-year overall and progression-free survival rates were 81% (95% CI, 62% to 100%) and 64% (95% CI, 39% to 89%), respectively. The estimated probability of nonrelapse mortality at 2 years was 6% (95% CI, 1% to 17%). Donor lymphocyte infusions induced a response in two patients progressing after allografting. CONCLUSION RIC followed by allogeneic stem-cell transplantation is feasible, has a low treatment-related mortality, and seems to be a promising salvage treatment for relapsed PTCL. These findings suggest that the existence of a graft-versus-T-cell lymphoma effect.
机译:目的外周T细胞淋巴瘤(PTCL)是一组以预后较差为特征的恶性肿瘤。我们进行了一项前瞻性研究,以研究降低强度的条件调节(RIC)和同种异体干细胞移植在复发性或难治性PTCL中的作用。患者和方法我们对17例接受挽救性化疗,随后进行RIC和异基因造血细胞移植的患者进行了II期试验。 RIC方案由thiotepa,氟达拉滨和环磷酰胺组成。急性移植物抗宿主病的预防包括环孢素和短期甲氨蝶呤。结果患者的中位年龄为41岁(范围为23至60岁)。 2例为原发性化学难治性,其中15例复发。自体移植后有8位患者(47%)病情复发。自入选研究之日起,中位随访28个月(范围从3到57个月),在17例患者中有14例还活着(12例完全缓解,1例部分缓解和1例疾病稳定),其中2例死亡由于进行性疾病而导致,其中一名因败血症而死于急性移植物抗宿主病。估计的三年总体生存率和无进展生存率分别为81%(95%CI,62%至100%)和64%(95%CI,39%至89%)。 2年时非复发性死亡的估计概率为6%(95%CI,1%至17%)。供体淋巴细胞输注在同种异体移植后进展的两名患者中引起了反应。结论RIC随后进行同种异体干细胞移植是可行的,具有较低的治疗相关死亡率,并且似乎是复发性PTCL的有希望的挽救性治疗。这些发现表明存在移植物抗T细胞淋巴瘤的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号